Financing - September 18, 2018
Lipum granted 2.2 million EUR
The Umeåbased startup company has been granted 2.2 million EUR from EU Horizon 2020, the EU framework program for research and development. The grant will go to Lipum’s ongoing development of a biological pharmaceutical for treatment of chronic inflammatory diseases, reports the company in their press release. Lipum has identified the novel target molecule Bile Salt-Stimulated Lipase […]
Financing - September 13, 2018
Ilya Pharma raises 3 million EUR
The funds, raised in a new target share issue, will facilitate continued growth and take the company through the first clinical study and planning of the upcoming Phase II study of its drug candidate, ILP-100, for faster wound healing. “We have been working hard on closing this issue during the summer and are delighted to […]
Collaboration - September 11, 2018
The first super session at NLSDays covered the key factor of financing
The Thuesday morning of NLSDays started off with a super session on Financing and both the expert panel and the presenting companies shared valuable insights. Starting and evolving a company requires funds and in this session, five Nordic life science companies at very different stages shared their experiences and their financing stories. First out was […]
Financing - September 10, 2018
RSP Systems raises EUR 3,85 million
The Danish diagnostics company announces that it has completed second closing of its Series B round, which brings in an additional EUR 3,85 million, making the round EUR 10,35 million in total. The proceeds will be used to fund clinical trials and to prepare for regulatory approval and market launch in Europe.´Existing, as well as […]
Financing - August 28, 2018
Beactica closes financing round
The Swedish drug discovery company has announced the completion of its latest financing round, providing funds that will be used to advance its internal pipeline of discovery-stage oncology programmes. The financing round was Beactica’s most successful to date, being almost 60% oversubscribed, it reports. Over one third of the investors were new to Beactica, raising […]
Financing - August 28, 2018
Major shareholder announcement in Zealand Pharma
As at 10 July 2018 Van Herk Investments B.V. holds nominally DKK 1,962,535 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 6.38% of the total share capital and total voting rights Zealand Pharma A/S. Van Herk Investments, based in the Netherlands, has a long track-record of investing in the life sciences […]
